Molecular subclasses of breast cancer: How do we define them? The IMPAKT 2012 working group statement

S Guiu; S Michiels; F André; J Cortes; C Denkert; A Di Leo; BT Hennessy; T Sorlie; C Sotiriou; N Turner; M Van de Vijver; G Viale; S Loi; JS Reis-Filho

Journal article

Molecular subclasses of breast cancer: How do we define them? The IMPAKT 2012 working group statement

S Guiu, S Michiels, F André, J Cortes, C Denkert, A Di Leo, BT Hennessy, T Sorlie, C Sotiriou, N Turner, M Van de Vijver, G Viale, S Loi, JS Reis-Filho

Annals of Oncology | ELSEVIER | Published : 2012

DOI: 10.1093/annonc/mds586

Abstract

The 2012 IMPAKT task force investigated the medical usefulness of current methods for the classification of breast cancer into the 'intrinsic' molecular subtypes (luminal A, luminal B, basal-like and HER2). A panel of breast cancer and/or gene expression profiling experts evaluated the analytical validity, clinical validity and clinical utility of two approaches for molecular subtyping of breast cancer: the prediction analysis of microarray (PAM)50 assay and an immuno-histochemical (IHC) surrogate panel including oestrogen receptor (ER), HER2 and Ki67. The panel found the currently available evidence on the analytical validity and clinical utility of Ki67 based on a 14% cut-off and PAM50 to ..

View full abstract